Compare SHFS & NXTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHFS | NXTS |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Agricultural Chemicals |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 2.4M |
| IPO Year | 2021 | 2021 |
| Metric | SHFS | NXTS |
|---|---|---|
| Price | $0.15 | $1.47 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 292.0K | 17.8K |
| Earning Date | 04-15-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 95.30 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,673,532.00 | $263,445.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.15 | $0.55 |
| 52 Week High | $9.18 | $23.80 |
| Indicator | SHFS | NXTS |
|---|---|---|
| Relative Strength Index (RSI) | 32.50 | 30.83 |
| Support Level | N/A | $0.55 |
| Resistance Level | $0.21 | $2.08 |
| Average True Range (ATR) | 0.01 | 0.14 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 12.72 | 19.48 |
SHF Holdings Inc is a financial services provider to cannabis-related businesses. It offers reliable access to banking solutions for cannabis, hemp, CBD, and ancillary operators, making communities safer, driving growth in local economies, and fostering long-term partnerships. The group, through its financial institution clients, implements accountability, transparency, monitoring, reporting, and risk mitigation measures while meeting Bank Secrecy Act obligations in line with FinCEN guidance on cannabis-related businesses. Its services include Program Management Support, Customer Generation, Ongoing Program Auditing, and Compliance Monitoring, among others.
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.